Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: Altimmune Q2 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $5.000K Down From $6.000K YoY

Author: Benzinga Newsdesk | August 08, 2024 07:23am
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported $5.000 thousand in sales this quarter. This is a 16.67 percent decrease over sales of $6.000 thousand the same period last year.

Posted In: ALT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist